Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
Negar Firouzabadi,1– 3 Maryam Dashti,1 Ali Dehshahri,4 Ehsan Bahramali5 1Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Nonco...
Guardado en:
Autores principales: | Firouzabadi N, Dashti M, Dehshahri A, Bahramali E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/32f4add3b7ee45ada71592699476ad7e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The IL-33/sST2 Axis in Thromboangiitis Obliterans
por: Sharebiani H, et al.
Publicado: (2020) -
Cyclodextrin Complexation as a Way of Increasing the Aqueous Solubility and Stability of Carvedilol
por: Sébastien Rigaud, et al.
Publicado: (2021) -
Transgenic Overexpression of Galectin-3 in Pancreatic β Cells Attenuates Hyperglycemia in Mice: Synergistic Antidiabetic Effect With Exogenous IL-33
por: Nemanja Jovicic, et al.
Publicado: (2021) -
Development of a Novel Homogeneous Nanoparticle-Based Assay for Rapid and High-Throughput Quantitation of the sST2 Protein in Human Serum
por: Gao S, et al.
Publicado: (2020) -
Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study
por: Brian Schwartz, et al.
Publicado: (2021)